Umbilical cord blood transplantation: Still growing and improving.
Umbilical cord blood transplantation: Still growing and improving.
复制标题
脐带血移植：仍在增长和改善
DOI：
10.1002/sctm.20-0495
复制
发表时间：
2021-11
影响因子：
6
通讯作者：
Sun Z
中科院分区：
文献类型：
--
作者：
Zhu X;Tang B;Sun Z
脐带血移植（UCBT）在临床上已经进行了30多年。近年来，脐带血（UCB）的生物学和免疫学特性得到了重新认识。以前被认为是医疗废物的UCB含有丰富的造血干细胞（hsc），这种干细胞naïve比其他干细胞更有活力，更容易扩增。UCB已被确定为同种异体造血干细胞移植（allo - HSCT）的可靠造血干细胞来源。与其他方法相比，UCBT有几个优点，包括对母亲和供体没有伤害，紧急使用的现货产品，不太严格的HLA匹配，慢性移植物抗宿主病（GVHD）的发病率和严重程度较低，并且可能有更强的移植物抗白血病效果，特别是移植前的微小残留疾病阳性患者。最近的研究表明，UCBT的结果得到了改善，与其他类型的同种异体造血干细胞移植相当。目前，UCBT广泛应用于恶性、非恶性、血液、先天性和代谢性疾病。在2013年之前，UCB银行的数量和移植程序呈指数增长。然而，2013年至2019年，亚洲和中国的ucbt数量稳步增长，但美国和欧洲的ucbt数量同比下降。在这篇综述中，我们重点介绍了过去30年UCBT的发展，面临的挑战和未来改进的策略，包括增加UCB数量，脐带血单位的选择，UCBT的调理方案和GVHD预防，以及UCBT并发症的管理。UCBT的利弊及改进策略。
Umbilical cord blood transplantation (UCBT) has been performed in the clinic for over 30 years. The biological and immunological characteristics of umbilical cord blood (UCB) have been re‐recognized in recent years. UCB, previously considered medical waste, is rich in hematopoietic stem cells (HSCs), which are naïve and more energetic and more easily expanded than other stem cells. UCB has been identified as a reliable source of HSCs for allogeneic hematopoietic stem cell transplantation (allo‐HSCT). UCBT has several advantages over other methods, including no harm to mothers and donors, an off‐the‐shelf product for urgent use, less stringent HLA match, lower incidence and severity of chronic graft‐vs‐host disease (GVHD), and probably a stronger graft‐vs‐leukemia effect, especially for minimal residual disease‐positive patients before transplant. Recent studies have shown that the outcome of UCBT has been improved and is comparable to other types of allo‐HSCT. Currently, UCBT is widely used in malignant, nonmalignant, hematological, congenital and metabolic diseases. The number of UCB banks and transplantation procedures increased exponentially before 2013. However, the number of UCBTs increased steadily in Asia and China but decreased in the United States and Europe year‐on‐year from 2013 to 2019. In this review, we focus on the development of UCBT over the past 30 years, the challenges it faces and the strategies for future improvement, including increasing UCB numbers, cord blood unit selection, conditioning regimens and GVHD prophylaxis for UCBT, and management of complications of UCBT. Advantages and disadvantages of UCBT and improving strategies.
登录
查看更多内容
影响因子：
15.3
作者：
Bock, Thomas A.;Orlic, Donald;Dunbar, Cynthia E.;Broxmeyer, Hal E.;Bodine, David M.
通讯作者：
Bodine, David M.
在HLA A，B，C和DRB1匹配的供体 - 辅助HLA对白血病和骨髓增生综合征的脐带血液移植后结果的影响：回顾性分析。
DOI：
10.1016/s1470-2045(11)70260-1
发表时间：
2011-12
期刊：
The Lancet. Oncology
影响因子：
--
作者：
Eapen M;Klein JP;Sanz GF;Spellman S;Ruggeri A;Anasetti C;Brown M;Champlin RE;Garcia-Lopez J;Hattersely G;Koegler G;Laughlin MJ;Michel G;Nabhan SK;Smith FO;Horowitz MM;Gluckman E;Rocha V;Eurocord-European Group for Blood and Marrow Transplantation;Netcord;Center for International Blood and Marrow Transplant Research
通讯作者：
Center for International Blood and Marrow Transplant Research
DOI：
10.1016/s2352-3026(17)30104-7
发表时间：
2017-07
期刊：
The Lancet. Haematology
影响因子：
--
作者：
Eapen M;Wang T;Veys PA;Boelens JJ;St Martin A;Spellman S;Bonfim CS;Brady C;Cant AJ;Dalle JH;Davies SM;Freeman J;Hsu KC;Fleischhauer K;Kenzey C;Kurtzberg J;Michel G;Orchard PJ;Paviglianiti A;Rocha V;Veneris MR;Volt F;Wynn R;Lee SJ;Horowitz MM;Gluckman E;Ruggeri A
通讯作者：
Ruggeri A
影响因子：
11.1
作者：
Baron, F.;Ruggeri, A.;Nagler, A.
通讯作者：
Nagler, A.
DOI：
10.1073/pnas.0603806103
发表时间：
2006-08-01
影响因子：
11.1
作者：
Chute, John P.;Muramoto, Garrett G.;McDonnell, Donald P.
通讯作者：
McDonnell, Donald P.